GCM
NBIX icon

Gallacher Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Gallacher Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,758
Closed -$232K – 319
2026
Q1 		$232K Buy
+1,758
New +$233K 0.09% 273

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Gallacher Capital Management's NBIX Position: Q2 2026 in Review

Gallacher Capital Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 1,758 shares — an estimated $232K sold.

Gallacher Capital Management first reported a position in NBIX in Q1 2026 and held it in 1 quarter. The position peaked at $232K in Q1 2026. 155 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Gallacher Capital Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Gallacher Capital Management sold 1,758 Neurocrine Biosciences shares in Q2 2026, an estimated $232K.
  • Gallacher Capital Management first reported a position in Neurocrine Biosciences in Q1 2026 and held it in 1 quarter.
  • Gallacher Capital Management's Neurocrine Biosciences position peaked at $232K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Gallacher Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.